Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gencay Hatiboglu

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Urologic Oncology|July 30, 2021
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancerCathleen Nientiedt, Jan Budczies, Volker Endris, et al.
Scientific Reports|November 14, 2018
Correlation between genomic index lesions and mpMRI and <sup>68</sup>Ga-PSMA-PET/CT imaging features in primary prostate cancerClaudia Kesch, Jan-Philipp Radtke, Axel Wintsche, et al.
Urologic Oncology|April 14, 2020
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panelCathleen Nientiedt, Volker Endris, Maximilian Jenzer, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Urologic Oncology|July 30, 2021
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancerCathleen Nientiedt, Jan Budczies, Volker Endris, et al.
Scientific Reports|November 14, 2018
Correlation between genomic index lesions and mpMRI and <sup>68</sup>Ga-PSMA-PET/CT imaging features in primary prostate cancerClaudia Kesch, Jan-Philipp Radtke, Axel Wintsche, et al.
Urologic Oncology|April 14, 2020
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panelCathleen Nientiedt, Volker Endris, Maximilian Jenzer, et al.
Pageof 6